Valuation: Genome & Company

Market Cap 220B 158M 135M 126M 116M 217M 15.1B 222M 1.5B 583M 7.57B 593M 580M 25.06B P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 202B 145M 124M 116M 106M 200M 13.88B 204M 1.37B 536M 6.95B 545M 533M 23.02B EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
85.14%
Yield 2024 *
-
Yield 2025 -
04-13 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
04-02 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
03-12 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
25-09-21 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
25-08-20 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
25-07-10 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
25-04-27 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
25-04-23 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
24-07-18 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-07-16 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-01-24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
1 day-4.76%
1 week-5.72%
Current month+28.20%
1 month+20.83%
3 months-34.60%
6 months-42.16%
Current year-38.88%
1 week 4,015
Extreme 4015
4,625
1 month 2,975
Extreme 2975
4,720
Current year 2,975
Extreme 2975
10,180
1 year 2,440
Extreme 2440
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
28,800
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 2015-09-23
Chief Executive Officer 55 2015-09-23
Director TitleAgeSince
Director/Board Member 55 2015-09-23
Director/Board Member 53 2015-09-23
Director/Board Member 62 -
Date Insider Type Main position Quantity % Market Cap.
5/9/25 Don

Chief Executive Officer

100,000 0.3217%
5/9/25 Free

Director

40,000 0.1287%
5/9/25 Free

Public Communications Manager

50,000 0.1608%
Change 5-day change 1-year change 3-year change Capi.($)
-4.76%-5.72%+68.88%-38.61% 166M
+1.01%+5.19%+4.37%+25.94% 51.22B
-0.90%+2.53%+472.55%+599.25% 45.38B
+2.55%+9.11%+20.75%+93.32% 41.97B
+1.12%+9.70%+40.04%+21.11% 42.15B
-0.93%-4.80%+17.39%+46.60% 31.95B
+0.56%+2.95% - - 16.73B
+1.24%+7.25%+36.87%+152.24% 17.1B
+0.03%+3.41%+7.12%+35.49% 14.76B
+1.86%+6.06%+92.20%+47.84% 13.91B
Average +0.18%+1.97%+84.46%+109.24% 27.53B
Weighted average by Cap. +0.70%+3.12%+103.68%+149.28%

Financials

2024 2025
Net sales 27.74B 19.91M 17.05M 15.91M 14.6M 27.43M 1.91B 27.97M 189M 73.57M 955M 74.77M 73.14M 3.16B 24.59B 17.65M 15.11M 14.1M 12.94M 24.31M 1.69B 24.79M 167M 65.19M 846M 66.26M 64.82M 2.8B
Net income -20.11B -14.44M -12.36M -11.53M -10.58M -19.88M -1.38B -20.27M -137M -53.33M -692M -54.2M -53.02M -2.29B -6.43B -4.61M -3.95M -3.69M -3.38M -6.35M -441M -6.48M -43.72M -17.04M -221M -17.32M -16.95M -732M
Net Debt -48.91B -35.1M -30.05M -28.04M -25.73M -48.35M -3.36B -49.3M -333M -130M -1.68B -132M -129M -5.57B -17.86B -12.82M -10.98M -10.24M -9.4M -17.66M -1.23B -18.01M -122M -47.36M -615M -48.14M -47.09M -2.04B
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
-
Date Price Change Volume
26-08-20 4,205.00 -4.76% 271,052
26-08-20 ₩4,415.00 +4.37% 324,927
26-08-19 ₩4,230.00 0.00% 291,298
26-08-18 ₩4,230.00 -8.44% 656,410
26-08-14 ₩4,620.00 +3.59% 333,630
  1. Stock Market
  2. Stocks
  3. A314130 Stock